Efficacy and Safety of Aromatase Inhibitor Combined with Growth Hormone in Korean Boys with Idiopathic Short Stature: A ...
Physiotherapist Nathan Scott shares advice on helping blokes have a better sex life... and some of his tips might surprise ...
“Our data shows that as many as 20% of breast cancer survivors on aromatase inhibitors will stop taking their medication ...
Investor's Business Daily on MSN
Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 130%
Biotech stock Olema Pharmaceuticals catapulted to a four-year high Tuesday after Roche unveiled positive results in breast ...
Evidence-based recommendations on ribociclib (Kisqali) with an aromatase inhibitor for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of ...
This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...
Dear Dr. Roach: I am an 80-year-old woman and a 25-year survivor of ovarian cancer. In the past three years, I have also had Merkel cell cancer, breast cancer, and now squamous cell cancer on my lip.
Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset. For patients with hormone receptor ...
In a recent study published in Nature Communications, researchers investigated the role of aromatase in the increased risk of autism spectrum disorder (ASD) observed in males prenatally exposed to ...
Mutations in ESR1 do not appear to confer breast cancer resistance to cyclin-dependent kinase (CDK)4/6 inhibitors, an analysis of clinical practice data suggested. Patients with metastatic hormone ...
BMI calculator Breast cancer patients with obesity may derive less of a benefit from aromatase inhibitors than patients of a “healthy” weight, according to researchers. Breast cancer patients with ...
Credit: Getty Images. Breast cancer patients with obesity may derive less of a benefit from aromatase inhibitors than patients of a “healthy” weight, according to researchers. Breast cancer patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results